What Drives Country Differences in Cost of Alzheimer’s Disease? An Explanation from Resource Use in the GERAS Study
Manuscript Number:
16-0449R2
Author(s):
Josep M. Argimon, Mark Belger, Giuseppe Bruno, Richard Dodel, Michael Happich, Josep Maria Haro, Roy W. Jones, Catherine Reed, Bruno Vellas, Anders Wimo
Disclosures
Josep M. Argimon
Consulting Fees:
I received in the past (not in the last two years) a fee for the design of GERAS study
Mark Belger
Equity:
Hold shares in Eli Lilly
Sponsors:
Full time employee of Eli Lilly as a Principal Research Scientist
Abbvie (2014), Novartis (2016), Pfizer (2017), Thieme Verlag (2014, 2015), Med Update (2014, 2015), Studienstiftung des deutschen Volkes (2014-2017)
Patents/Royalties
6 patents
Grants
Agency:
Baxter
Dates:
2012-2016
Agency:
Deutsche Parkinson Vereinigung
Dates:
(2008-2016),
Agency:
Faber Stiftung
Dates:
2016
Agency:
Hector Stiftung
Dates:
2010-2014
Agency:
Internationale Parkinson Fonds
Dates:
2013-2015
Agency:
Michael J Fox Foundation
Dates:
2016-2017
Agency:
AOK Gesundheitskasse Hessen
Dates:
2015-2016
Agency:
AOK Gesundheitskasse Sachsen und Thüringen
Dates:
2015-2016
Michael Happich
Equity:
I own stocks from Eli Lilly
Sponsors:
I am employee at Eli Lilly
Josep Maria Haro
Consulting Fees:
I have received consulting fees from Lilly, Lundbeck and Otsuka
Lecture Fees:
I have received consulting fees from Lilly and Otsuka
Roy W. Jones
Consulting Fees:
Advisory Boards for Eli Lilly, MSD, Novartis and Otsuka; Data Monitoring Committee member for studies sponsored by Lundbeck, Novartis/Banner/NIH and Roche.
Lecture Fees:
Lecture fees and/or chairing symposia for Eli Lilly and Biogen
Catherine Reed
Equity:
minor shareholder Eli Lilly and Company
Sponsors:
part-time employee at Eli Lilly and Company
Bruno Vellas
Consulting Fees:
Lily, Merck, Otsuka, Acadia, nestle
Grants
Agency:
nestle, lily, pierre fabre, acadia, merck
Anders Wimo
Consulting Fees:
Eli Lilly
Biogen
Axoivant
Nutricia
Lundbeck
Novartis